Protocol Ledger

NCT06246149 · Phase III · RECRUITING

Adjuvant Tebentafusp in High Risk Ocular Melanoma

Interventional Phase III clinical trial protocol NCT06246149 sponsored by European Organisation for Research and Treatment of Cancer - EORTC in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-11-11 Enrollment: 290 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06246149
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)290 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06246149
Protocol FieldVerified Registry Value
NCT IdentifierNCT06246149
Consolidated Lead SponsorEuropean Organisation for Research and Treatment of Cancer - EORTC
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment290 participants (ESTIMATED)
Registered Start Date2024-11-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06246149
Hospital Research SiteLocationSite Profile
Northwell Health/Center for Advanced MedicineLake Success, NYOpen Hospital Dossier ->
Cliniques Universitaires Saint-LucBrussels, BelgiumOpen Hospital Dossier ->
Centre Antoine-LacassagneNice, FranceOpen Hospital Dossier ->
Erasmus MCRotterdam, NetherlandsOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI